SynthesisNeurosciences (Riyadh, Saudi Arabia)2026
A Systematic Comparative Review of Antipsychotic Efficacy and Safety in the Treatment of Hiccups.
Synthesis in Neurosciences (Riyadh, Saudi Arabia), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate and compare the safety and effectiveness of antipsychotic medications for the treatment of hiccups, thereby guiding clinicians toward evidence-based treatment guidelines. Hiccups are often benign and self-limiting; however, they can become persistent and intractable, adversely affecting the quality of life. Antipsychotics have been identified as a therapeutic option for the management of hiccups; however, the available evidence supporting their safety and efficacy has not been synthesized. Methods: This review utilized the revised Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The Cochrane Risk of Bias Assessment Tool was modified to evaluate the quality of the selected studies. The search strategy included terms related to or describing hiccups and antipsychotics. Research articles in English published between 1974 and March 2024 were searched in different databases. Duplicates and eligibility criteria were used to screen articles. Results: A search of Medline, Scopus, and Web of Science yielded 1537 articles, of which 1042 were retained after removing duplicates, and 16 met the inclusion criteria. The studies that met the inclusion criteria were all case reports, case series, or retrospective studies, with no randomized trials. A few antipsychotics have been shown to totally or partially alleviate hiccups. Nine studies reported that hiccups were completely resolved in patients treated with 10-25 mg oral and intramuscular chlorpromazine, 1-2 mg oral and intramuscular haloperidol, 2.5-10 mg oral olanzapine, 25-150 mg tetrabenazine, and 3 mg oral risperidone. Adverse events were documented in 7 of the studies. Conclusion: Chlorpromazine and olanzapine are effective antipsychotics for hiccup treatment. However, more evidence-based studies and controlled clinical trials are needed to confirm the efficacy and minimize the side effects. PROSPERO registration: (CRD42024511626).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.